瑞普生物(300119) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached ¥821,616,475.90, representing a 20.00% increase compared to ¥684,664,200.42 in the same period last year[5] - Net profit attributable to shareholders was ¥115,984,657.96, up 28.45% from ¥90,296,367.92 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥93,461,027.11, reflecting a 19.65% increase from ¥78,112,210.30 in the previous year[5] - Basic and diluted earnings per share increased by 30.05% to ¥0.2549 from ¥0.1960[5] - The company's net profit for the current period is 120,104,766.30, an increase from 99,204,884.37 in the previous period, representing a growth of approximately 21.1%[25] - Operating profit for the current period is 137,340,410.30, compared to 111,111,675.09 in the previous period, indicating an increase of about 23.6%[25] - The total comprehensive income for the current period is 120,104,766.30, compared to 99,204,884.37 in the previous period, showing an increase of about 21.1%[26] - The basic and diluted earnings per share for the current period are both 0.2549, up from 0.1960 in the previous period, indicating an increase of approximately 29.8%[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥8,062,345,190.71, a 1.21% increase from ¥7,965,793,053.87 at the end of the previous year[5] - Total liabilities increased to RMB 2,978,808,279.25 from RMB 2,958,832,996.02, indicating a rise of approximately 0.7%[23] - The company's retained earnings grew to RMB 1,901,990,815.32 from RMB 1,786,006,157.36, an increase of about 6.5%[23] Cash Flow - The company's cash flow from operating activities decreased by 18.97% to ¥73,531,140.14 from ¥90,749,055.61 in the same period last year[5] - The cash flow from operating activities for the current period is 73,531,140.14, down from 90,749,055.61 in the previous period, a decrease of about 18.9%[28] - The net cash flow from investing activities is -94,813,371.70, a decrease from 172,357,951.83 in the previous period, reflecting a decline of approximately 155%[28] - The company’s total cash and cash equivalents at the end of the period are 450,642,854.36, down from 606,305,656.08, a decrease of about 25.7%[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,251[12] - The largest shareholder, Li Shoujun, holds 35.95% of shares, totaling 167,474,479 shares, with 125,605,859 shares pledged[12] - The company has repurchased 10,093,859 shares, representing 2.17% of total shares, held in a special repurchase account[13] - The top ten shareholders hold a significant portion of shares, with the top four shareholders alone holding over 47%[12] - The company has a total of 130,885,585 restricted shares at the end of the reporting period, with 19,080 shares released during the period[15] - The company’s stock incentive plan includes various executives with restricted shares set to unlock according to the 2022 plan[15] - The company repurchased a total of 6,404,251 shares, accounting for 1.3748% of the total share capital, with a total payment of RMB 120 million (excluding transaction fees) as of March 31, 2025[18] Research and Development - Research and development expenses rose by 31.64% to ¥47,940,755.91, driven by increased investment in independent R&D projects[10] - Research and development expenses rose to 47,940,755.91 from 36,418,931.94, reflecting a growth of approximately 31.7%[25] Strategic Initiatives - The company has completed the acquisition of 56.3129% of Tianjin Zhongrui Supply Chain Management Co., Ltd. to enhance its strategic layout in the pet health sector[17] - The company aims to improve market share and brand recognition through strategic acquisitions and partnerships in the pet product sector[17] - The company has changed its name from "Tianjin Ruipu Biotechnology Co., Ltd." to "Ruipu Biological Co., Ltd." to better align with its current industry layout[16] Financial Metrics - Total operating revenue for the current period reached RMB 821,616,475.90, an increase from RMB 684,664,200.42 in the previous period, reflecting a growth of approximately 20.0%[24] - Total operating costs amounted to RMB 694,874,920.33, up from RMB 578,891,036.50 in the previous period, indicating an increase of about 20.0%[24] - Accounts receivable rose to RMB 1,104,140,588.74 from RMB 1,039,789,034.46, representing an increase of about 6.2%[21] - Inventory increased to RMB 511,261,875.85 from RMB 499,573,319.96, showing a growth of approximately 2.3%[21] - The company incurred financial expenses of 8,772,440.95, which is an increase from 5,549,604.84, representing a growth of approximately 57.5%[25] Fair Value Gains - The company reported a significant increase in fair value gains from non-current financial assets, which rose by 148.82% to ¥25,328,670.23 compared to ¥10,179,495.72 in the previous year[10] - The company experienced a 63.07% increase in receivables financing, totaling ¥12,267,033.56, attributed to increased bill business during the period[10]